Cargando…
Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors
SUMOylation is a post-translational modification (PTM) whereby members of the Small Ubiquitin-like MOdifier (SUMO) family of proteins are conjugated to lysine residues in target proteins. SUMOylation has been implicated in a wide range of physiological and pathological processes, and much attention...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524998/ https://www.ncbi.nlm.nih.gov/pubmed/32892251 http://dx.doi.org/10.1007/s11302-020-09723-0 |
_version_ | 1783588650373611520 |
---|---|
author | Zanella, Camila A. Tasca, Carla I. Henley, Jeremy M. Wilkinson, Kevin A. Cimarosti, Helena I. |
author_facet | Zanella, Camila A. Tasca, Carla I. Henley, Jeremy M. Wilkinson, Kevin A. Cimarosti, Helena I. |
author_sort | Zanella, Camila A. |
collection | PubMed |
description | SUMOylation is a post-translational modification (PTM) whereby members of the Small Ubiquitin-like MOdifier (SUMO) family of proteins are conjugated to lysine residues in target proteins. SUMOylation has been implicated in a wide range of physiological and pathological processes, and much attention has been given to its role in neurodegenerative conditions. Due to its reported role in neuroprotection, pharmacological modulation of SUMOylation represents an attractive potential therapeutic strategy in a number of different brain disorders. However, very few compounds that target the SUMOylation pathway have been identified. Guanosine is an endogenous nucleoside with important neuromodulatory and neuroprotective effects. Experimental evidence has shown that guanosine can modulate different intracellular pathways, including PTMs. In the present study we examined whether guanosine alters global protein SUMOylation. Primary cortical neurons and astrocytes were treated with guanosine at 1, 10, 100, 300, or 500 μM at four time points, 1, 6, 24, or 48 h. We show that guanosine increases global SUMO2/3-ylation in neurons and astrocytes at 1 h at concentrations above 10 μM. The molecular mechanisms involved in this effect were evaluated in neurons. The guanosine-induced increase in global SUMO2/3-ylation was still observed in the presence of dipyridamole, which prevents guanosine internalization, demonstrating an extracellular guanosine-induced effect. Furthermore, the A1 adenosine receptor antagonist DPCPX abolished the guanosine-induced increase in SUMO2/3-ylation. The A2A adenosine receptor antagonist ZM241385 increased SUMOylation per se, but did not alter guanosine-induced SUMOylation, suggesting that guanosine may modulate SUMO2/3-ylation through an A1-A2A receptor interaction. Taken together, this is the first report to show guanosine as a SUMO2/3-ylation enhancer in astrocytes and neurons. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11302-020-09723-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7524998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-75249982020-10-14 Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors Zanella, Camila A. Tasca, Carla I. Henley, Jeremy M. Wilkinson, Kevin A. Cimarosti, Helena I. Purinergic Signal Original Article SUMOylation is a post-translational modification (PTM) whereby members of the Small Ubiquitin-like MOdifier (SUMO) family of proteins are conjugated to lysine residues in target proteins. SUMOylation has been implicated in a wide range of physiological and pathological processes, and much attention has been given to its role in neurodegenerative conditions. Due to its reported role in neuroprotection, pharmacological modulation of SUMOylation represents an attractive potential therapeutic strategy in a number of different brain disorders. However, very few compounds that target the SUMOylation pathway have been identified. Guanosine is an endogenous nucleoside with important neuromodulatory and neuroprotective effects. Experimental evidence has shown that guanosine can modulate different intracellular pathways, including PTMs. In the present study we examined whether guanosine alters global protein SUMOylation. Primary cortical neurons and astrocytes were treated with guanosine at 1, 10, 100, 300, or 500 μM at four time points, 1, 6, 24, or 48 h. We show that guanosine increases global SUMO2/3-ylation in neurons and astrocytes at 1 h at concentrations above 10 μM. The molecular mechanisms involved in this effect were evaluated in neurons. The guanosine-induced increase in global SUMO2/3-ylation was still observed in the presence of dipyridamole, which prevents guanosine internalization, demonstrating an extracellular guanosine-induced effect. Furthermore, the A1 adenosine receptor antagonist DPCPX abolished the guanosine-induced increase in SUMO2/3-ylation. The A2A adenosine receptor antagonist ZM241385 increased SUMOylation per se, but did not alter guanosine-induced SUMOylation, suggesting that guanosine may modulate SUMO2/3-ylation through an A1-A2A receptor interaction. Taken together, this is the first report to show guanosine as a SUMO2/3-ylation enhancer in astrocytes and neurons. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11302-020-09723-0) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-09-05 2020-09 /pmc/articles/PMC7524998/ /pubmed/32892251 http://dx.doi.org/10.1007/s11302-020-09723-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Zanella, Camila A. Tasca, Carla I. Henley, Jeremy M. Wilkinson, Kevin A. Cimarosti, Helena I. Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors |
title | Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors |
title_full | Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors |
title_fullStr | Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors |
title_full_unstemmed | Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors |
title_short | Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors |
title_sort | guanosine modulates sumo2/3-ylation in neurons and astrocytes via adenosine receptors |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524998/ https://www.ncbi.nlm.nih.gov/pubmed/32892251 http://dx.doi.org/10.1007/s11302-020-09723-0 |
work_keys_str_mv | AT zanellacamilaa guanosinemodulatessumo23ylationinneuronsandastrocytesviaadenosinereceptors AT tascacarlai guanosinemodulatessumo23ylationinneuronsandastrocytesviaadenosinereceptors AT henleyjeremym guanosinemodulatessumo23ylationinneuronsandastrocytesviaadenosinereceptors AT wilkinsonkevina guanosinemodulatessumo23ylationinneuronsandastrocytesviaadenosinereceptors AT cimarostihelenai guanosinemodulatessumo23ylationinneuronsandastrocytesviaadenosinereceptors |